Research programme: NASH gene therapy - Amsterdam Molecular Therapeutics

Drug Profile

Research programme: NASH gene therapy - Amsterdam Molecular Therapeutics

Alternative Names: AMT-012

Latest Information Update: 16 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-alcoholic steatohepatitis

Most Recent Events

  • 18 Nov 2009 No development reported for Non-alcoholic steatohepatitis in Netherlands (Parenteral)
  • 25 May 2009 Early research in Non-alcoholic steatohepatitis in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top